

Once-A-Day

# Adalat<sup>®</sup>CC

## nifedipine

EXTENDED  
RELEASE  
TABLETS

30mg, 60mg & 90mg

## Real Value for Real People with Hypertension

### Real Therapeutic Value

- The benefits of long-acting nifedipine —effective calcium blockade for hypertension\*

### Real Human Value

- Once-daily regimen for tolerability and convenience
- Frequency and type of side effects are typical of dihydropyridine calcium channel blockers. The dose-dependent incidence of peripheral edema was 18%-29% vs. 10% for placebo and for headache was 16%-22% vs. 13% for placebo. Flushing/heat sensation, dizziness, and fatigue/asthenia were each reported at an incidence of 4%<sup>1</sup>

### Real Economic Value

- Lower Average Wholesale Price (AWP) than frequently-prescribed, once-daily calcium channel blockers<sup>2</sup>

Projected annual savings<sup>2</sup> per hypertensive patient for frequently-prescribed, once-daily calcium channel blocker therapy

Medication	Recommended initial dose <sup>2</sup>	Cost of annual therapy based on initial dose <sup>2</sup>	Potential annual patient savings with Adalat <sup>®</sup> CC
Adalat <sup>®</sup> CC	30 mg	\$306.97	
Procardia XL <sup>®</sup>	30 mg	\$432.34	\$125.00
Calan <sup>®</sup> SR or Isoptin <sup>®</sup> SR	180 mg	\$396.65	\$89.68
Verelan <sup>®</sup>	120 mg	\$374.27	\$67.30
Cardizem <sup>®</sup> CD	180 mg	\$437.27	\$130.30
Dilacor <sup>®</sup> XR	180 mg	\$361.06	\$54.09
Norvasc <sup>®</sup>	5 mg	\$413.73	\$106.76

Procardia XL (nifedipine) and Norvasc (amlodipine besylate) are registered trademarks of Pfizer Labs Division, Pfizer Inc. Calan SR (verapamil HCl), Isoptin SR (verapamil HCl), Verelan (verapamil HCl), Cardizem CD (diltiazem HCl), and Dilacor XR (diltiazem HCl) are registered trademarks of G.D. Searle & Co., Knoll Pharmaceutical Co., Lederle Laboratories, a Division of American Cyanamid Co., Marion Merrell Dow Inc., and Rhône-Poulenc Rorer Pharmaceuticals Inc., respectively.

\*Adalat CC is not indicated for angina. It should be taken on an empty stomach. Careful titration may be necessary when switching between Procardia XL<sup>®</sup> and Adalat CC. As with all distinct pharmacologic entities, switching from one to another necessitates careful titration and patient monitoring.

<sup>1</sup> Calculations based on suggested Average Wholesale Price (AWP).<sup>2</sup> AWP is from a published price list and may or may not represent the actual price to pharmacists or consumers.

**“Sure I consider cost... but only after I consider efficacy and safety. That’s why I chose Adalat<sup>®</sup> CC as the calcium blocker for Rudy.” —H. M., MD, Pittsburgh**

---

## ANNOUNCEMENTS

### NKF ANNUAL SPRING MEETINGS

The National Kidney Foundation (NKF) Fourth Annual Spring Clinical Nephrology Meetings/Consultative Nephrology Program will be held March 23–26, 1995, at the Sheraton Washington Hotel, Washington, DC. Continuing Medical Education credits are available. The National Kidney Foundation Spring Clinical Nephrology Meetings offer six separate programs targeted toward nephrologists, renal and nonrenal dietitians, social workers, nurses, and technicians. There will be a special 2-day program designed for primary care physicians and physician assistants. For registration information, call 1-800-622-9010.

### SIXTH INTERNATIONAL WORKSHOP ON DEVELOPMENTAL NEPHROLOGY

The Sixth International Workshop on Developmental Nephrology will be held on August 23–25, 1995, at Airlie House in Airlie, VA. The workshop is intended to provide a comprehensive review of renal developmental physiology and cell and molecular biology and renal growth. Topics will include renal embryogenesis and differentiation, receptors and cell signaling, cell effectors, vasoactive agents, growth factors, renal maldevelopment, and developmental pathophysiology. For further information, please contact Robert L. Chevalier, MD, Department of Pediatrics, Box 386, University of Virginia School of Medicine, Charlottesville, VA 22908. Phone: 804-924-5093, FAX: 804-982-3561.

### THE SIXTH INTERNATIONAL ANCA WORKSHOP

This workshop will be held from June 28 to July 1, 1995, in Paris. Main topics will include function of neutrophil granules, neutrophil activation, experimental models of ANCA (antineutrophil cytoplasm antibodies)-related diseases, nature of ANCA antigen and autoantibody, spectrum and classification of ANCA-associated diseases, and therapeutic approaches in vasculitis. For further information and program, contact the Secretariat: ANCA Workshop c/o Ph Lesavre, Département de Néphrologie, Hôpital Necker, 161 Rue de Sèvres, 75743 Paris Cédex 15, France; FAX: 33.1.45.66.51.33.

### CURRENT TOPICS IN PATHOLOGY V: LIVER, GI, KIDNEY BIOPSY PATHOLOGY

The Continuing Medical Education program on Current Topics in Pathology V will be held April 28–30, 1995, at the Westin Canal Place Hotel, 100 Rue Iberville, New Orleans, LA 70130; (504)566-7006. It is sponsored by Tulane University Medical Center, Department of Pathology and the Tulane University Medical Center, Office of Continuing Education. Credit: 16.5 credit hours, Category 1; Course Director: Sanda Clejan, MD. Cost: \$150, 1 day; \$275, 2 days; \$400, 3 days. Specialty: Pathology, GI, Nephrology, Internal Medicine. Contact: Pamala Schmidt, Office of Continuing Education at (504)588-5466 or 1-800-588-5300; FAX: (504)588-1779.

---

### CORRECTIONS

The following sentence should have been added to the article "Vitamin D Receptor Gene Expression in Mammalian Kidney" by L. Liu *et al.* (*JASN* 1994;5:1251–1258): Lanting Liu was supported by a postdoctoral research fellowship award from the American Heart Association, Oklahoma Affiliate.

Please note the following correction to the abstract by S.M. Mauer entitled "Differences in Severity of Acute Rejection Grading Between Superficial Cortex and Deep Cortex in Renal Allograft Biopsies (*JASN* 1994;5:1018; 34P)". The altered sentence should read: "Using the Wilcoxon signed rank test we found significantly greater histologic changes of AR in the DC vs. SC for the following parameters ..."